Enhanced Growth Inhibition of Osteosarcoma by Cytotoxic Polymerized Liposomal Nanoparticles Targeting the Alcam Cell Surface Receptor
Open Access
- 1 January 2012
- journal article
- research article
- Published by Hindawi Limited in Sarcoma
- Vol. 2012, 1-11
- https://doi.org/10.1155/2012/126906
Abstract
Osteosarcoma is the most common primary malignancy of bone in children, adolescents, and adults. Despite extensive surgery and adjuvant aggressive high-dose systemic chemotherapy with potentially severe bystander side effects, cure is attainable in about 70% of patients with localized disease and only 20%–30% of those patients with metastatic disease. Targeted therapies clearly are warranted in improving our treatment of this adolescent killer. However, a lack of osteosarcoma-associated/specific markers has hindered development of targeted therapeutics. We describe a novel osteosarcoma-associated cell surface antigen, ALCAM. We, then, create an engineered anti-ALCAM-hybrid polymerized liposomal nanoparticle immunoconjugate (-AL-HPLN) to specifically target osteosarcoma cells and deliver a cytotoxic chemotherapeutic agent, doxorubicin. We have demonstrated that-AL-HPLNs have significantly enhanced cytotoxicity over untargeted HPLNs and over a conventional liposomal doxorubicin formulation. In this way,-AL-HPLNs are a promising new strategy to specifically deliver cytotoxic agents in osteosarcoma.
Keywords
Funding Information
- National Institutes of Health (U54 CA19367, P50 CA092131, P30 CA016042, IIP-1143342)
This publication has 30 references indexed in Scilit:
- An Engineered Cysteine-Modified Diabody for Imaging Activated Leukocyte Cell Adhesion Molecule (ALCAM)-Positive TumorsMolecular Imaging & Biology, 2011
- Partially polymerized liposomes: stable against leakage yet capable of instantaneous release for remote controlled drug deliveryNanotechnology, 2011
- A novel class of photo-triggerable liposomes containing DPPC:DC8,9PC as vehicles for delivery of doxorubcin to cellsBiochimica et Biophysica Acta (BBA) - Biomembranes, 2011
- Cys-diabody Quantum Dot Conjugates (ImmunoQdots) for Cancer Marker DetectionBioconjugate Chemistry, 2009
- Lipid-Based Nanoparticles as Pharmaceutical Drug Carriers: From Concepts to ClinicCritical Reviews in Therapeutic Drug Carrier Systems, 2009
- Multidrug resistance mediated by ABC transporters in osteosarcoma cell lines: mRNA analysis and functional radiotracer studiesNuclear Medicine and Biology, 2006
- ALCAM/CD166 is up‐regulated in low‐grade prostate cancer and progressively lost in high‐grade lesionsThe Prostate, 2002
- Activated leukocyte cell adhesion molecule (CD166/ALCAM): Developmental and mechanistic aspects of cell clustering and cell migrationEuropean Journal of Cell Biology, 2002
- Activated Leukocyte Cell Adhesion Molecule/CD166, a Marker of Tumor Progression in Primary Malignant Melanoma of the SkinThe American Journal of Pathology, 2000
- Effects of substituent-induced strain on the electronic structure of polydiacetylenesThe Journal of Chemical Physics, 1986